drugset / Trial / NCT00113113
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.
Timeline
- Start
- 2001-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rubitecan | Unknown | — | Oral |